To Compare the Efficacy and Safety of Perrigo's Product to an FDA Approved Product for the Treatment of Glaucoma or Ocular Hypertension in Both Eyes

PHASE3CompletedINTERVENTIONAL

Enrollment

447

Participants

Timeline

Start Date

May 28, 2021

Primary Completion Date

March 11, 2022

Study Completion Date

June 21, 2022

Conditions

Glaucoma, Open-AngleOcular Hypertension

Interventions

DRUG

Brinzolamide/brimonidine ophthalmic suspension

Test product

DRUG

Simbrinza 0.2%/1% Ophthalmic Suspension

Reference product

Trial Locations (1)

James D. Branch Ophthalmology, Winston-Salem